1,5-disubstituted imidazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of eye and bone diseases

Details for Australian Patent Application No. 2003233731 (hide)

International Classifications

Event Publications

28 August 2003 Complete Application Filed

Priority application(s): 60/386,641 06.06.02 US

19 February 2004 Application Open to Public Inspection

Published as AU-A-2003233731

16 March 2006 Assignment before Grant

Billot, Xavier; Young, Robert; Merck Frosst Canada & Co. The application has been assigned to Billot, Xavier; Young, Robert; Merck Frosst Canada Ltd.

8 January 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.